Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center

Area of Science:

• Neurology
• Neuroimaging
• Movement Disorders

Background:

• Clinical diagnosis of parkinsonism is often imprecise, leading to misdiagnosis.
• 123I-ioflupane SPECT (DaTscan) is a neuroimaging agent used to differentiate essential tremor from parkinsonian syndromes.
• Previous studies highlight the clinical utility of DaTscan in movement disorder centers.

Purpose of the Study:

• To assess the quantitative impact of DaTscan imaging on diagnostic certainty.
• To evaluate the influence of DaTscan results on subsequent clinical decisions.
• To determine the correlation between DaTscan findings and the laterality of clinical symptoms.

Main Methods:

• A prospective, observational study was conducted over 18 months in a movement disorder center.
• Four specialists completed questionnaires before and after DaTscan imaging.
• Patient data and clinical assessments were analyzed in conjunction with imaging results.

Main Results:

• DaTscan imaging was performed on 27 patients, with 81.4% showing abnormal results.
• Post-imaging diagnostic certainty for parkinsonism significantly increased with abnormal scans and decreased with normal scans.
• Clinical management was impacted in 88.9% of patients, including medication changes (18 patients) and psychological effects (11 patients).

Conclusions:

• DaTscan imaging enhances physician confidence in diagnosing parkinsonism.
• The neuroimaging results can influence patient psychological states.
• DaTscan serves as a valuable adjunct to clinical evaluation in select parkinsonism cases.